Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

It’s happened to all of us: you find the perfect model for your needs — a bracket, a box, a cable clip, but it only comes in STL, and doesn’t quite fit. That problem will never happen if you’re using ...

Ohio State changed the tide of The Game and beat Michigan 27-9 to snap a four-game losing streak in the rivalry. With the return of wide receivers Carnell Tate and Jeremiah Smith from injury, Ohio ...

Between the two industry giants, Fidelity’s robust platform pulls slightly ahead Gordon Scott has been an active investor and technical analyst or 20+ years. He is a Chartered Market Technician (CMT).

How to master the process that’s transforming management by Darrell Rigby, Jeff Sutherland and Hirotaka Takeuchi Agile innovation methods have revolutionized information technology. Over the past 25 ...

Clay Halton was a Business Editor at Investopedia and has been working in the finance publishing field for more than five years. He also writes and edits personal finance content, with a focus on ...